1. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials pulmonary arterial hypertension. Eur Heart J. 2009;30:394-403. doi: 10.1093/eurheartj/ehp022
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-49.
3. Kane GC, Maradit-Kremers H, Slusser J, et al. Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest. 2011;139(6):1285-93.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-30. doi:10.1164/rccm.200510-1668OC
5. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). doi: 10.1183/13993003.00740-2017
6. Волков А.В., Мартынюк Т.В., Юдкина Н.Н., Данилов Н.М., Глухова С.И., Гусева Н.Г., Чазова И.Е., Насонова В.А. Выживаемость пациентов с легочной артериальной гипертензией, ассоциированной с системной склеродермией. Терапевтический архив. 2012;84(5):24-8 [Volkov A, Martynyuk T, Yudkina N, Danilov N, Gluhova S, Guseva N, Chazova I, Nasonov V. Survival of patients with pulmonary arterial hypertension associated with systemic sclerosis. Therapeutic Archive. 2012;84(5):24-8 (In Russ.)].
7. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017
8. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017 Aug 3;50(2):pii: 1700889. doi: 10.1183/13993003.00889-2017
9. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Intern J Cardiology. 2013;168(2):871-80. doi: 10. 1016/j.ijcard.2012.10.026
10. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46(4):903-75. doi:10.1183/13993003.01032-2015
11. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation. 2009;119:2250-94. doi: 10.1161/CIRCULATIONAHA.109.192230
12. Федеральные рекомендации по диагностике и лечению легочной гипертензии. http://cr.rosminzdrav.ru/ [Federal recommendations for the diagnosis and treatment of pulmonary hypertension (In Russ.)].
13. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-33. doi:10.1056/NEJMoa1503184

________________________________________________

1. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials pulmonary arterial hypertension. Eur Heart J. 2009;30:394-403. doi: 10.1093/eurheartj/ehp022
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-49.
3. Kane GC, Maradit-Kremers H, Slusser J, et al. Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest. 2011;139(6):1285-93.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-30. doi:10.1164/rccm.200510-1668OC
5. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). doi: 10.1183/13993003.00740-2017
6. Volkov A, Martynyuk T, Yudkina N, Danilov N, Gluhova S, Guseva N, Chazova I, Nasonov V. Survival of patients with pulmonary arterial hypertension associated with systemic sclerosis. Therapeutic Archive. 2012;84(5):24-8 (In Russ.).
7. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017
8. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017 Aug 3;50(2):pii: 1700889. doi: 10.1183/13993003.00889-2017
9. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Intern J Cardiology. 2013;168(2):871-80. doi: 10. 1016/j.ijcard.2012.10.026
10. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46(4):903-75. doi:10.1183/13993003.01032-2015
11. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation. 2009;119:2250-94. doi: 10.1161/CIRCULATIONAHA.109.192230
12. Federal recommendations for the diagnosis and treatment of pulmonary hypertension (In Russ.).
13. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-33. doi:10.1056/NEJMoa1503184

И.Е. Чазова, Т.В. Мартынюк от имени авторов

Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия 

________________________________________________

I.E. Chazova, T.V. Martynyuk on behalf of the team of co-authors

A.L.Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia